EPS for Eyegate Pharmaceuticals, Inc. (EYEG) Expected At $-0.26; Katy Industries (KT) Sentiment Is 1.86

February 8, 2018 - By Adrian Erickson

Analysts expect Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) to report $-0.26 EPS on February, 22.They anticipate $0.12 EPS change or 31.58% from last quarter’s $-0.38 EPS. After having $-0.24 EPS previously, Eyegate Pharmaceuticals, Inc.’s analysts see 8.33% EPS growth. The stock increased 12.29% or $0.0799 during the last trading session, reaching $0.7299. About 708,612 shares traded or 76.49% up from the average. Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has declined 40.33% since February 8, 2017 and is downtrending. It has underperformed by 57.03% the S&P500.

KT Corporation provides telecommunications services in Korea. The company has market cap of $5.91 billion. The firm offers fixed-line telephone services, including local, domestic long-distance, and international long-distance fixed-line and voice over Internet protocol telephone services, as well as interconnection services; Internet phone services; broadband Internet access and other Internet-related services, including Internet protocol television services; and data communication services, including leased line and dedicated broadband Internet connection services to institutional customers. It has a 10.55 P/E ratio. It also provides mobile voice and data telecommunications services; and credit card processing and other financial services, as well as sells mobile handsets.

The stock decreased 1.40% or $0.19 during the last trading session, reaching $13.73. About 1.35 million shares traded or 58.13% up from the average. KT Corporation (KT) has risen 15.78% since February 8, 2017 and is uptrending. It has underperformed by 0.92% the S&P500.

Silchester International Investors Llp holds 18.16% of its portfolio in KT Corporation for 26.03 million shares. Mittleman Brothers Llc owns 1.41 million shares or 8.96% of their US portfolio. Moreover, Somerset Capital Management Llp has 4.79% invested in the company for 1.38 million shares. The Florida-based Kopernik Global Investors Llc has invested 4.5% in the stock. Segantii Capital Management Ltd, a Hong Kong-based fund reported 770,128 shares.

Among 2 analysts covering Eyegate Pharmaceuticals (NASDAQ:EYEG), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eyegate Pharmaceuticals had 2 analyst reports since November 12, 2015 according to SRatingsIntel. The stock of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has “Buy” rating given on Wednesday, December 23 by Chardan Capital Markets. Maxim Group initiated Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) rating on Thursday, November 12. Maxim Group has “Buy” rating and $11 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: